Roth Capital analyst Kyle Bauser raised the firm’s price target on iRadimed (IRMD) to $98 from $90 and keeps a Buy rating on the shares, citing higher forward estimates and confidence in the business after the company reported Q3 sales and EPS above the firm’s and consensus estimates and raised full-year guidance.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRMD: